Progression-free survival

62% estimated 1-year PFS rate (95% CI: 45, 75)2

Chart of progression-free survival over time Chart of progression-free survival over time

Pinch to zoom

  • PFS and OS were secondary endpoints of the ZUMA-2 phase 2, single-arm, open-label study and were not the primary objectives of the study
  • PFS and OS data are not included in the USPI. PFS and OS data are descriptive and should be carefully interpreted in light of the single-arm design
  • TECARTUS® is currently under accelerated approval for MCL based on overall response rate and durability of response. Further clinical studies will be conducted

83% estimated 1-year OS rate (95% CI: 24, NE)3

  • Median OS was not reached at a median follow-up of 12.3 months

It is estimated that at 1 year postinfusion, approximately 82% of patients
with a CR will be progression free2

CI=confidence interval; CR=complete response; MCL=mantle cell lymphoma; NE=not estimable; OS=overall survival; PFS=progression-free survival; R/R=relapsed or refractory; USPI=US Prescribing Information.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file. Kite Pharma, Inc; 2020. 3. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342.